AQR Capital Management
IMDX

AQR Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

AQR Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-676
Closed -$20K – 2261
2022
Q1 		$20K Sell
676
-1,736
-72% -$55.5K ﹤0.01% 2205
2021
Q4 		$105K Sell
2,412
-315
-12% -$18.1K ﹤0.01% 2147
2021
Q3 		$194K Sell
2,727
-3,190
-54% -$293K ﹤0.01% 2156
2021
Q2 		$679K Buy
5,917
+3,449
+140% +$337K ﹤0.01% 1765
2021
Q1 		$256K Buy
+2,468
New +$234K ﹤0.01% 2051
2020
Q1 		– Sell
-1,707
Closed -$77K – 2123
2019
Q4 		$77K Sell
1,707
-1,782
-51% -$64.3K ﹤0.01% 2096
2019
Q3 		$147K Buy
+3,489
New +$137K ﹤0.01% 2053

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

AQR Capital Management's IMDX Position: Q2 2022 in Review

AQR Capital Management sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 676 shares — an estimated $20K sold.

AQR Capital Management first reported a position in IMDX in Q3 2019 and held it in 7 quarters. The position peaked at $679K in Q2 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

  • AQR Capital Management reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
  • AQR Capital Management sold 676 Insight Molecular Diagnostics shares in Q2 2022, an estimated $20K.
  • AQR Capital Management first reported a position in Insight Molecular Diagnostics in Q3 2019 and held it in 7 quarters.
  • AQR Capital Management's Insight Molecular Diagnostics position peaked at $679K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.